eXoZymes Inc. (EXOZ)

In the past six months, eXoZymes announced a successful scale-up of NCT production, achieving over 99% conversion. The company unveiled a refreshed brand identity and website, signaling a sharpened strategic focus. eXoZymes provided an update on its operations through the fiscal year ended December 31, 2025, reporting increased operating expenses and a net loss. As of December 31, 2025, the company had $3.04 million in cash and filed an S-3 registration statement in January 2026. The company's CCO was scheduled to present a NCT solution at the MISTA Symposium in March 2026, and a webinar was held to discuss Q4 and full-year 2025 results. Over the last six months, EXOZ stock has seen a decline of 53.8%.

Information regarding specific demand seasonality for eXoZymes, Inc.'s products and services is not publicly available. Demand may be less subject to seasonal fluctuations compared to consumer-facing goods, given the company's focus on high-value products in the pharmaceutical, nutraceutical, and specialty chemical sectors.

eXoZymes, Inc. is a biotechnology company that pioneers a cell-free biomanufacturing platform using AI-enhanced enzymes to produce high-value chemicals, medicines, and fuels, aiming to provide a sustainable and scalable alternative to traditional chemical production methods. The company operates within the Biotechnology industry and its core technology combines enzymes with artificial intelligence to transform biomass into valuable compounds without living cells. Its product pipeline includes chemicals, medicines/pharmaceuticals, nutraceuticals, and fragrances. The company's business model involves developing and deploying its exozyme-based biomanufacturing solutions through spin-outs, joint ventures, and licensing agreements.

eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California. The company aims to translate its biomanufacturing capabilities into commercial assets across wellness, industrial, and pharmaceutical markets. The company seeks partners with relevant manufacturing footprints to share costs, risks, and revenue.

eXoZymes has actively worked on its brand reputation and has experienced both positive developments and ongoing challenges. The successful scale-up and validation of NCT production and the launch of a redesigned corporate website bolster the company's technical credibility and brand image. eXoZymes has been selected as a core industry partner in an NSF-funded initiative and holds leadership roles in BioMADE governance committees. The company acknowledges facing skepticism due to past disappointments in the synthetic biology industry and its reputation is heavily tied to achieving commercialization milestones and securing financing.

eXoZymes, Inc. has a mix of institutional and individual ownership. Institutions held 48% of the shares, insiders owned a significant proportion, and the general public held a 27% stake. MDB Capital Holdings LLC, Christopher A. Marlett, and Anthony Digiandomenico each hold 45.41% of the shares. Other major owners include Tyler Paz Korman, Paul Hideo Opgenorth, James Ulrich Bowie, and Mohammad Hayat. Vanguard Group Inc and Geode Capital Management LLC are institutional owners.